EXECUTIVE ENGAGEMENTS
POOL
5211
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
832
Interactions with Platform & by Email
PARTICIPANTS
167
Unique # Participated
VALIDATIONS
38
Responses Validated*
COMPANIES
266
Responses Validated*
* Login for a full stack data experience
DATE
MAY 2022
TABLES
148
PAGES
727
EDITION
9
PRICE
USD 4950
CODE
MCP10061
*Engagement stats are ongoing and dynamic
RESEARCH MODULES
EXECUTIVES
HIGHLIGHTS & REPORT INDEX
What's New for 2022?
» Global competitiveness and key competitor percentage market shares
» Market presence across multiple geographies - Strong/Active/Niche/Trivial
» Online interactive peer-to-peer collaborative bespoke updates
» Access to our digital archives and MarketGlass Research Platform
» Complimentary updates for one year
Amid the COVID-19 crisis, the global market for Active Pharmaceutical Ingredients (API) estimated at US$176.1 Billion in the year 2020, is projected to reach a revised size of US$264.1 Billion by 2027, growing at a CAGR of 6% over the period 2020-2027.Innovative, one of the segments analyzed in the report, is projected to grow at a 5.7% CAGR to reach US$180.5 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Generic segment is readjusted to a revised 6.6% CAGR for the next 7-year period. This segment currently accounts for a 30.4% share of the global Active Pharmaceutical Ingredients (API) market.
The Active Pharmaceutical Ingredients (API) market in the U.S. is estimated at US$61 Billion in the year 2020. The country currently accounts for a 34.66% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$42 Billion in the year 2027 trailing a CAGR of 6.2% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.3% and 5.6% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 5.4% CAGR while Rest of European market (as defined in the study) will reach US$42 Billion by the year 2027.
SELECT PLAYERS
AbbVie Inc.; Aurobindo Pharma Ltd.; BASF SE; Boehringer Ingelheim International GmbH; Cipla Ltd.; Dr. Reddy’s Laboratories Ltd.; Lupin Ltd.; Merck KGaA; Novartis International AG; Pfizer Inc.; Sun Pharmaceutical Industries Ltd.; Teva Pharmaceutical Industries Ltd.; Viatris Inc.
SEGMENTS
» Type (Innovative, Generic) » Synthesis (Synthetic, Biotech) » Application (Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic, Other Applications)
GEOGRAPHIES
» World » USA » Canada » Japan » China » Europe » France » Germany » Italy » UK » Rest of Europe » Asia-Pacific » Rest of World
TABLE OF CONTENTS
| I. METHODOLOGY |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Influencer Market Insights |
| World Market Trajectories |
| Impact of Covid-19 and a Looming Global Recession |
| 2020: A Year of Disruption & Transformation |
| As the Race between the Virus & Vaccines Intensifies, Where is the World Economy Headed in 2021 |
| EXHIBIT 1: World Economic Growth Projections (Real GDP, Annual % Change) for 2020 through 2022 |
| COVID-19 Alters Pharmaceutical Industry and API Production Dynamics |
| COVID-19 Exposes US Pharmaceutical Makers to Risk of Supply Shortages, Driving the Need to Revamp Domestic Industry Structure |
| Pandemic Leads US to Focus on Stockpiling & Localized Manufacturing to Rectify Supply Chain Flaws |
| Revamping Local Production Capacity |
| Knock-on Effect of COVID-19 on API Availability Incites Players to Reconfigure Supply Chain |
| COVID-19 Pandemic: A Wake-Up Call for API Seekers to Mitigate Supply Risks |
| Short-Term Strategies |
| Long-Term Strategies |
| Unprecedented Global Push to Expedite COVID-19 Vaccine Development to Spur Demand for APIs |
| EXHIBIT: Global Percentage of Individuals Vaccinated by Geographic Region for 2021 through 2025 |
| EXHIBIT: Number of CMO Sites for Vaccine Production in Select Countries: 2020 |
| Active Pharmaceutical Ingredients (API) – Global Key Competitors Percentage Market Share in 2022 (E) |
| Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E) |
| Active Pharmaceutical Ingredients: A Prelude |
| Outlook |
| Regional Landscape |
| US CDMOs to Gain from Mounting Concerns Over Excess Reliance On Chinese APIs |
| China Continues to Remain a Major Hub |
| COVID-19 Brings Europe’s High Reliance on APIs Sourced from Outside under Spotlight |
| India Strives to Increase API Production to Attain Self Reliance in Pharmaceutical Production |
| Recent Market Activity |
| world Brands |
| 2. FOCUS ON SELECT PLAYERS |
| 3. MARKET TRENDS & DRIVERS |
| Sustained Increase in Drug R&D Spending to Drive API Market |
| EXHIBIT: Pharmaceutical R&D Spending Worldwide (USD Billion): 2015-2025 |
| Increased API Sourcing Creates the need for More Scrutiny of Suppliers for Best Quality Products |
| Preference for Specialized CDMO Contractors on the Rise |
| Strong Rise in Pharmaceutical Sales to Drive Demand |
| EXHIBIT: Global Prescription Drug Sales (In US$ Billion) for the Years 2017, 2019, 2021, 2023 & 2025 |
| The AIC Approach for Faster Assessment of Viable Drug Candidates |
| Drug Makers Embrace Digital Technology Amidst COVID-19 Crisis |
| EXHIBIT: Digital Transformation Spending in US$ Billion in Pharma Sector: 2020 and 2027 |
| AI Finds Growing Application in Drug Discovery and Development |
| Microdosing Beneficial for the Formulation of High Potency Ingredients |
| Growing Penetration of Generic Drugs Augments Market Prospects |
| EXHIBIT: Leading Drugs Facing Patent Expiry in the US in 2020 |
| EXHIBIT 3: Global Generic Drugs Market Size (in $ Billion) for the Years 2016, 2019, 2020 & 2025 |
| Increasing Interest in Biopharmaceuticals Supports Market Demand |
| EXHIBIT: Global Biologic Drugs Market Size (in US$ Billion) for the Years 2019, 2022 & 2025 |
| Rising Number of Biologics Approvals Augurs Well |
| EXHIBIT: The U.S FDA Biologic NME Approvals for Years 2016 through 2020 |
| EXHIBIT: Sponsor Market Cap for the FDA-Approved Biologic FDA NMEs (2020) |
| Growing Biosimilars Market Create Opportunities for APIs |
| EXHIBIT: Global Biosimilars Market in US$ Billion: 2020 & 2025 |
| Growing Attention Towards Personalized Medicine Spurs Demand for Complex API |
| EXHIBIT: Global Personalized Medicine Market: Revenues in US$ Million for the Years 2019, 2021, 2023 and 2025 |
| Increasing Sales of OTC Drugs Presents an Opportunity for APIs |
| EXHIBIT 9: Global OTC Drugs Market Breakdown by Product (in %): 2020E |
| Growing Prevalence of Infectious Diseases to Spur Growth |
| EXHIBIT: Infectious Diseases Remain Major Cause of Death in Under Developed Regions: Breakdown of Leading Causes of Death in Sub-Saharan Africa (in %) |
| EXHIBIT: Global Number of Deaths Caused Due to Communicable Diseases (In 000s) |
| Rising Incidence of Cancer & Need to Reduce Cancer-Related Mortality Spell Increased Demand |
| EXHIBIT: Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040 |
| EXHIBIT 5: Global Breakdown of Total Number of Cancer Cases by Type: 2020 |
| Increasing Prevalence of Chronic Disorders Fuels Market Growth |
| EXHIBIT: World Diabetes and Population Statistics (2019, 2030 & 2045) |
| Rising Incidence of Cardiovascular Diseases Revs Up Opportunities |
| EXHIBIT: Hypertension Prevalence (%) Worldwide by Region in Male and Females Aged 25+ Years |
| EXHIBIT: Fatalities by Heart Conditions: Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others |
| Upsurge in ANDA Approvals Bodes Well |
| Aging Population & Increasing Burden of Chronic Diseases Spurs Pharma Product Sales, Driving Market Growth |
| EXHIBIT 5: Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050 |
| 4. GLOBAL MARKET PERSPECTIVE |
| World Recent Past, Current & Future Analysis for Innovative by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Innovative by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Innovative by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Generic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Generic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Generic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Synthetic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Synthetic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Synthetic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Biotech by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Biotech by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Biotech by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Cardiovascular Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Endocrinology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Endocrinology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Endocrinology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for CNS & Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for CNS & Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for CNS & Neurology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Gastroenterology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Gastroenterology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Gastroenterology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Orthopedic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Orthopedic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Orthopedic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Active Pharmaceutical Ingredients (API) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2021 & 2027 |
| III. MARKET ANALYSIS |
| UNITED STATES |
| Active Pharmaceutical Ingredients (API) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E) |
| USA Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2021 & 2027 |
| USA Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Synthesis - Percentage Breakdown of Value Sales for Synthetic and Biotech for the Years 2012, 2021 & 2027 |
| USA Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Application - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications for the Years 2012, 2021 & 2027 |
| CANADA |
| Canada Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2021 & 2027 |
| Canada Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Synthesis - Percentage Breakdown of Value Sales for Synthetic and Biotech for the Years 2012, 2021 & 2027 |
| Canada Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Application - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications for the Years 2012, 2021 & 2027 |
| JAPAN |
| Active Pharmaceutical Ingredients (API) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E) |
| Japan Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2021 & 2027 |
| Japan Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Synthesis - Percentage Breakdown of Value Sales for Synthetic and Biotech for the Years 2012, 2021 & 2027 |
| Japan Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Application - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications for the Years 2012, 2021 & 2027 |
| CHINA |
| Active Pharmaceutical Ingredients (API) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E) |
| China Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2021 & 2027 |
| China Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Synthesis - Percentage Breakdown of Value Sales for Synthetic and Biotech for the Years 2012, 2021 & 2027 |
| China Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Application - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications for the Years 2012, 2021 & 2027 |
| EUROPE |
| Active Pharmaceutical Ingredients (API) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E) |
| Europe Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2021 & 2027 |
| Europe Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Synthesis - Percentage Breakdown of Value Sales for Synthetic and Biotech for the Years 2012, 2021 & 2027 |
| Europe Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Application - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications for the Years 2012, 2021 & 2027 |
| Europe Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Active Pharmaceutical Ingredients (API) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2021 & 2027 |
| FRANCE |
| Active Pharmaceutical Ingredients (API) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E) |
| France Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2021 & 2027 |
| France Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Synthesis - Percentage Breakdown of Value Sales for Synthetic and Biotech for the Years 2012, 2021 & 2027 |
| France Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Application - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications for the Years 2012, 2021 & 2027 |
| GERMANY |
| Active Pharmaceutical Ingredients (API) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E) |
| Germany Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2021 & 2027 |
| Germany Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Synthesis - Percentage Breakdown of Value Sales for Synthetic and Biotech for the Years 2012, 2021 & 2027 |
| Germany Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Application - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications for the Years 2012, 2021 & 2027 |
| ITALY |
| Italy Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2021 & 2027 |
| Italy Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Synthesis - Percentage Breakdown of Value Sales for Synthetic and Biotech for the Years 2012, 2021 & 2027 |
| Italy Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Application - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications for the Years 2012, 2021 & 2027 |
| UNITED KINGDOM |
| Active Pharmaceutical Ingredients (API) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E) |
| UK Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2021 & 2027 |
| UK Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Synthesis - Percentage Breakdown of Value Sales for Synthetic and Biotech for the Years 2012, 2021 & 2027 |
| UK Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Application - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications for the Years 2012, 2021 & 2027 |
| REST OF EUROPE |
| Rest of Europe Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2021 & 2027 |
| Rest of Europe Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Synthesis - Percentage Breakdown of Value Sales for Synthetic and Biotech for the Years 2012, 2021 & 2027 |
| Rest of Europe Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Application - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications for the Years 2012, 2021 & 2027 |
| ASIA-PACIFIC |
| Active Pharmaceutical Ingredients (API) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E) |
| Asia-Pacific Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2021 & 2027 |
| Asia-Pacific Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Synthesis - Percentage Breakdown of Value Sales for Synthetic and Biotech for the Years 2012, 2021 & 2027 |
| Asia-Pacific Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Application - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications for the Years 2012, 2021 & 2027 |
| REST OF WORLD |
| Rest of World Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of World Historic Review for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of World 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2021 & 2027 |
| Rest of World Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of World Historic Review for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of World 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Synthesis - Percentage Breakdown of Value Sales for Synthetic and Biotech for the Years 2012, 2021 & 2027 |
| Rest of World Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of World Historic Review for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of World 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Application - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications for the Years 2012, 2021 & 2027 |
| IV. COMPETITION |
| Total Companies Profiled: 266 |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com